CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hermanto, U.
Right arrow Articles by Wang, L.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hermanto, U.
Right arrow Articles by Wang, L.-H.
Cell Growth & Differentiation Vol. 11, 655-664, December 2000
© 2000 American Association for Cancer Research


Articles

Inhibition of Mitogen-activated Protein Kinase Kinase Selectively Inhibits Cell Proliferation in Human Breast Cancer Cells Displaying Enhanced Insulin-like Growth Factor I-mediated Mitogen-activated Protein Kinase Activation 1

Ulrich Hermanto, Cong S. Zong and Lu-Hai Wang2

Department of Microbiology, Mount Sinai School of Medicine, New York, New York 10029-6574

Abstract

Mitogen-activated protein (MAP) kinase mediates cell proliferation, cell differentiation, and cell survival by regulating signaling pathways activated by receptor protein tyrosine kinases (RPTKs), including the insulin-like growth factor 1 receptor (IGF-IR). We analyzed the upstream signaling components of the MAP kinase pathway, including RPTKs, in human breast cancer cell lines and found that some of those components were overexpressed. Importantly, signaling molecules such as IGF-IR, insulin receptor, and insulin receptor substrate 1, leading to the MAP kinase pathway, were found to be concomitantly overexpressed within certain tumor lines, i.e., MCF-7 and T-47D. When compared with the nonmalignant and other breast tumor lines examined, MCF-7 and T-47D cells displayed a more rapid, robust, and sustained MAP kinase activation in response to insulin-like growth factor I (IGF-I) stimulation. By contrast, IGF-I treatment led to a sustained down-regulation of MAP kinase in those lines overexpressing ErbB2-related RPTKs. Interestingly, blocking the MAP kinase pathway with PD098059 had the greatest antiproliferative effect on MCF-7 and T-47D among the normal and tumor lines tested. Furthermore, addition of an IGF-IR blocking antibody to growth medium attenuated the ability of PD098059 to suppress the growth of MCF-7 and T-47D cells. Thus, our study suggests that concomitant overexpression of multiple signaling components of the IGF-IR pathway leads to the amplification of IGF-I-mediated MAP kinase signaling and resultant sensitization to PD098059. The enhanced sensitivity to PD098059 implies an increased requirement for the MAP kinase pathway in those breast cancer cells, making this pathway a potential target in the treatment of selected breast malignancies.




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
L. Laviola, A. Natalicchio, S. Perrini, and F. Giorgino
Abnormalities of IGF-I signaling in the pathogenesis of diseases of the bone, brain, and fetoplacental unit in humans
Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E991 - E999.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
P. D. Ryan and P. E. Goss
The Emerging Role of the Insulin-Like Growth Factor Pathway as a Therapeutic Target in Cancer
Oncologist, January 1, 2008; 13(1): 16 - 24.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
Y. Zhang, M. Karas, H. Zhao, S. Yakar, and D. LeRoith
14-3-3{sigma} Mediation of Cell Cycle Progression Is p53-independent in Response to Insulin-like Growth Factor-I Receptor Activation
J. Biol. Chem., August 13, 2004; 279(33): 34353 - 34360.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
T. Ahmad, G. Farnie, N. J. Bundred, and N. G. Anderson
The Mitogenic Action of Insulin-like Growth Factor I in Normal Human Mammary Epithelial Cells Requires the Epidermal Growth Factor Receptor Tyrosine Kinase
J. Biol. Chem., January 16, 2004; 279(3): 1713 - 1719.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. K. Maloney, J. L. McLaughlin, N. E. Dagdigian, L. M. Garrett, K. M. Connors, X.-M. Zhou, W. A. Blattler, T. Chittenden, and R. Singh
An Anti-Insulin-like Growth Factor I Receptor Antibody That Is a Potent Inhibitor of Cancer Cell Proliferation
Cancer Res., August 15, 2003; 63(16): 5073 - 5083.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Caristi, J. L. Galera, F. Matarese, M. Imai, S. Caporali, M. Cancemi, L. Altucci, L. Cicatiello, D. Teti, F. Bresciani, et al.
Estrogens Do Not Modify MAP Kinase-dependent Nuclear Signaling during Stimulation of Early G1 Progression in Human Breast Cancer Cells
Cancer Res., September 1, 2001; 61(17): 6360 - 6366.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 2000 by the American Association of Cancer Research.